Please try another search
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research, development, manufacture, sale, and distribution of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that has completed Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is also developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate in Phase 2 clinical trial to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn’s disease. Incannex Healthcare Inc. is headquartered in Sydney, Australia.
Name | Age | Since | Title |
---|---|---|---|
Joel Bradley Latham | 35 | 2023 | President, CEO & Executive Director |
Peter Widdows | 58 | 2023 | Independent Non-Executive Director |
Troy Robert Valentine | 50 | 2023 | Non-Executive Chairman |
Paul Liknaitzky | - | 2020 | Member of Medical Advisory Board |
Mark Bleackley | - | - | Chief Scientific Officer, Head of Programs & Member of the Advisory Board |
George E. Anastassov | 61 | 2023 | Independent Non-Executive Director & Member of Advisory Board |
Robert Bruce Clark | 64 | 2023 | Independent Non-Executive Director |
Lekhram Changoer | 57 | 2023 | CTO & Member of Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review